IPO

Remus Pharmaceuticals Limited IPO

NSE SME

Listed On: May 29, 2023 at ₹ 1711.25

₹ 245800 /200 Shares
*Min Investment

Check Allotment

17 May, 2023

Open Date

19 May, 2023

Close Date

24 May, 2023

Allotment Date

29 May, 2023

Listing Date
Remus Pharmaceuticals Limited IPO Issue Details
  • Issue Price ₹1150-1229 per equity share
  • Face Value ₹10 Per Equity Share
  • Issue Price Fresh Issue : 388,000 shares(aggregating up to ₹47.69 Cr)
  • Listing at NSE SME
  • List Price 1711.25
  • Listing Date 2023-05-29
  • Lead Manager Beeline Capital Advisors Pvt Ltd
  • Registrar Link Intime India Private Ltd
Remus Pharmaceuticals Limited IPO Details
  • Retail Portion N/A
Remus Pharmaceuticals Limited IPO Documents
DRHP
RHP
Remus Pharmaceuticals Limited IPO Details


Remus Pharmaceuticals Limited IPO is an SME IPO, priced at ₹1150-1229 per equity share. The equity shares have a face value of ₹10 Per Equity Share each and will be listed on the NSE SME platform.

The IPO bidding window is open from May 17, 2023 to May 19, 2023. The allotment is expected to be finalized on May 24, 2023, and the tentative listing date is May 29, 2023.


The registrar of the IPO is Link Intime India Private Ltd, and

Read More
Remus Pharmaceuticals Limited IPO Subscription Analysis And Details
Retail
49.81x
Total
57.21x
As on QIB / NII Retail Total
Shares Offered / Reserved / 1,944,118 3,470,400
Day 1 17-05-23 06:00 PM
/ x 2.85 x 1.43 x
Day 2 18-05-23 06:00 PM
/ x 10.79 x 6.36 x
Day 3 19-05-23 06:00 PM
/ x 49.81 x 57.21 x
Total No of Applications
48,370
Remus Pharmaceuticals Limited Valuations
Earnings Per Share (EPS) ₹N/A/-
P/E Ratio N/A
RoNW N/A%
Net Asset Value (NAV) - Post Issue ₹N/A/-
Remus Pharmaceuticals Limited Company Financials
In Lakhs
In Lakh
30-Dec-22 31-Mar-22 31-Mar-21 31-Mar-20
Assets 3,352.96 1,590.93 1,104.96 530.36
Revenue 3,361.20 2,543.71 1,922.45 1,276.89
Profit After Tax 643.90 338.57 102.58 81.16
About Remus Pharmaceuticals Limited Company

Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.

The product offerings of the company can be classified into two major categories:
APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.

Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.

The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.

As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.

The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.

Read More
Remus Pharmaceuticals Limited - Promoter(s)

Mr. Arpit Deepakkumar Shah

Ms. Roma Vinodbhai Shah

Mr. Swapnil Jatinbhai Shah

Mrs. Anar Swapnil Shah

Pre Issue Share Holding : 92.82%

Post Issue Share Holding : %

Remus Pharmaceuticals Limited IPO - Issue Objectives
1

To Meet Working Capital Requirements

2

Funding investments for acquisitions and general corporate purposes

3

To meet Public Issue Expenses